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oropharyngeal cancer may potentially improve local control. We evaluated the feasibility of this approach
using volumetric-modulated arc therapy (RapidArc) and compared these plans with ﬁxed-ﬁeld intensity-
modulated radiotherapy (IMRT) focal dose escalation plans. Materials and methods: An initial study of 20
patients compared RapidArc with ﬁxed-ﬁeld IMRT using standard dose prescriptions. From this cohort, 10
were included in a dose escalation planning study. Dose escalation was applied to 18F-FDG-PET–positive
regions in the primary tumor at dose levels of 5% (DL1), 10% (DL2), and 15% (DL3) above standard radical
dose (65 Gy in 30 fractions). Fixed-ﬁeld IMRT and double-arc RapidArc plans were generated for each
dataset. Dose-volume histograms were used for plan evaluation and comparison. The Paddick conformity
index (CIPaddick) and monitor units (MU) for each plan were recorded and compared. Both IMRT and
RapidArc produced clinically acceptable plans and achieved planning objectives for target volumes. Dose
conformity was signiﬁcantly better in the RapidArc plans, with lower CIPaddick scores in both primary
(PTV1) and elective (PTV2) planning target volumes (largest difference in PTV1 at DL3; 0.81  0.03
[RapidArc] vs. 0.77  0.07 [IMRT], p  0.04). Maximum dose constraints for spinal cord and brainstem were
not exceeded in both RapidArc and IMRT plans, but mean doses were higher with RapidArc (by 2.7  1 Gy
for spinal cord and 1.9  1 Gy for brainstem). Contralateral parotid mean dose was lower with RapidArc,
which was statistically signiﬁcant at DL1 (29.0 vs. 29.9 Gy, p  0.01) and DL2 (29.3 vs. 30.3 Gy, p  0.03).
MU were reduced by 39.8–49.2% with RapidArc (largest difference at DL3, 641  94 vs. 1261  118, p 
0.01). 18F-FDG-PET–guided focal dose escalation in oropharyngeal cancer is feasible with RapidArc.
Compared with conventional ﬁxed-ﬁeld IMRT, RapidArc can achieve better dose conformity, improve
contralateral parotid sparing, and uses fewer MU.
 2013 American Association of Medical Dosimetrists.
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rIntroduction
The rate of locoregional relapse for squamous cell carcinoma (SCC)
of the oropharynx is high, with up to 50% of locally advanced tumors
relapsing within 5 years.1,2 This is despite signiﬁcant improvements
in treatment with concurrent chemoradiotherapy, biologic agents,
and altered fractionation.1–3 These tumors often display features as-
ociated with an aggressive disease phenotype and intrinsic radiore-
istance, which could account for this high rate of local treatment
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ancer Centre, Royal Surrey County Hospital, Guildford, Surrey GU2 7XX, UK.
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ttp://dx.doi.org/10.1016/j.meddos.2012.05.002ailure.4 Because there is an establisheddose–response relationship in
hese tumors, escalating the radiation dose may improve tumor con-
rol and treatment outcomes. This has previously been difﬁcult to
mplementwith conventional radiotherapy techniques because of the
ncreased risk of radiation-induced toxicity. However, with advances
n radiotherapy techniques, such as intensity-modulated radiother-
py (IMRT), highly conformal dose distributions and improved spar-
ng of organs at risk (OARs) can be achieved, which could potentially
llow for dose escalation strategies.
A phase I/II trial conducted at the RoyalMarsdenHospital (UK) has
eported high rates of locoregional control with dose escalation using
MRT in locally advanced laryngeal and hypopharyngeal tumors.5 In
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M. Teoh et al. / Medical Dosimetry 38 (2013) 18-24 19this study, dose escalation was applied to a large planning target vol-
ume (PTV) that included the entire primary tumor subsite and in-
volved neck lymph node levels. Although toxicity was reported to be
acceptable, signiﬁcant acute and late side effects were still observed.
An alternative approachwould be to target speciﬁc regionswithin the
tumor that are at the highest risk of local relapse for dose escalation.
This approach is supportedby the observation thatmost local relapses
(53–97%) occur within the high-dose radiotherapy volume.6 The an-
icipated toxicity would be reduced because the volumes receiving
ery high radiation doses would be signiﬁcantly smaller.7
The success of a focal dose escalation strategy would depend on
the accurate detection of these biologically radioresistant regions.
This could be achieved with functional imaging techniques, such as
ﬂuorine-18-ﬂuorodeoxyglucose-positron emission tomography (18F-
DG-PET).8 Head and neck squamous cell carcinoma (SCC) is com-
monly 18F-FDG–avid,with up to 90–100% of these tumors identiﬁable
n 18F-FDG-PET.8 Furthermore, there is evidence that the degree of
18F-FDG uptake is correlated with inferior locoregional control and
urvival.9 This could imply a more aggressive biologic phenotype in
18F-FDG–positive tumors, which may require higher radiation doses
o achieve tumor control. There have been few planning studies that
ave evaluated focal dose escalation to 18F-FDG-PET–positive regions
n head and neck cancer using conventional ﬁxed-ﬁeld IMRT.10 The
hase I trials conducted by Madani et al.11,12 are the only published
studies thathave reportedonclinical outcomes,with early results show-
ing excellent response and local control rates. Although more studies
evaluating IMRT are in progress, further developments in treatment de-
livery techniquesmay offer alternative solutions to allow clinical imple-
mentation of 18F-FDG-PET–guided focal dose escalation.
One such recent advancement is the development of volumetric-
modulated arc therapy (VMAT) technology.13 Very few studies have
valuated VMAT in the context of focal dose escalation in head and neck
ancer.14,15 An early planning study by Korreman et al.14 evaluated the
easibilityof targetingcopper-61-diacetyl-bis(N4-methylthiosemicarba-
zone) (61Cu-ATSM)–avid regions of hypoxia using RapidArc in a single
ead and neck case. The study concluded that RapidArcwas able to pro-
uce deliverable planswith good dose conformity. The results of a plan-
ing study conducted by the Ghent group,15 which compared VMAT
with ﬁxed-ﬁeld IMRT to dose-escalate 18F-FDG–positive regions in head
nd neck cancer, were presented at a recent international conference.
reliminary results indicated improvedbiologic conformalityandorgans
t risk (OAR) sparing with VMAT.
The aims of our planning study were to:
. Evaluate RapidArc compared with conventional ﬁxed-ﬁeld IMRT
in locally advanced oropharyngeal SCC using standard dose
prescriptions.
. Evaluate the feasibility of focal dose escalation to 18F-FDG–positive
regions within the primary tumor using RapidArc.
3. Evaluate the RapidArc dose escalation plans comparedwith ﬁxed-
ﬁeld IMRT dose escalation plans to assess the difference in dose
distributions between these 2 techniques.
Methods and Materials
Patients, volumes, and planning objectives
Twenty patients with locally advanced oropharyngeal SCC receiving radical radio-
therapy at the Royal Surrey County Hospital between August 2008 and July 2011 were
evaluated in the initial planning study (standard dose). All patients had routine imaging
(magnetic resonance imaging [MRI] of head and neck, computed tomography [CT] of
the head and neck/thorax/upper abdomen) for staging of their disease before treat-
ment. Ten patients from this initial cohort had additional 18F-FDG-PET/CT scans as part
f their staging procedure and were selected for the dose escalation (boost) planning
tudy. A customized thermoplastic mask was used for immobilization, and radiother-
py planning CT scans were taken with contrast (Niopam, Bracco, Milan, Italy) en-
anced acquisition at 1- to 3-mm slice thickness.
16–18Target volumes were deﬁned according to ICRU 50, 62, and 83 guidelines.
Gross tumor volume (GTV) was deﬁned as the visible tumor, seen as the area of en-
bhancement on the planning CT and delineated taking into consideration the ﬁndings
from clinical examination and diagnostic imaging. The primary clinical target volume
(CTV1) included the GTV with a 1- to 1.5-cmmargin, expanded to include neighboring
and nodal areas requiring irradiation to a radical dose and edited away fromanatomical
barriers. The elective CTV (CTV2) included the neck nodal regions that are considered at
risk of microscopic involvement and delineated according to the Consensus guide-
lines.19,20 A 3D margin of 3 mm was added to CTV1 and CTV2 to produce the primary
planning target volume (PTV1) and elective PTV (PTV2), respectively. OAR including the
spinal cord, brainstem, and parotid glands were also contoured.
For the boost study, a biologic GTV (GTVB) was deﬁned as the
18F-FDG–positive
regionwithin the primary tumor as seen on the 18F-FDG-PET/CT scan. 18F-FDG–positive
egions in the neck lymph nodes were not included in the dose-escalated volume. This
as because in our clinical setting, patientswith residual nodal disease after radiother-
py can undergo a neck dissection. A freehand delineation method based on visual
nterpretation of the PET images was used to deﬁne the PET-positive regions, which
ere then contoured on the radiotherapy planning CT scan. Rigid coregistration of the
ET and planning CT images was not performed because patients were not in identical
ositions for both scans.
The dose prescriptions to PTV1 and PTV2 were 65 and 54 Gy in 30 daily fractions,
espectively. For the boost study, dose escalation to GTVB was applied in dose levels of
5% (dose level 1, DL1); 10% (dose level 2, DL2); and 15% (dose level 3, DL3) above the
PTV1 prescription dose. The equivalent dose in 2-Gy fractions (EQD2) for each dose
level was calculated using:
EQD2Dd 


2 ,
where D  total dose, d  dose per fraction, and / of 2 and 3 for late toxicity used
for calculation.21 The total dose to GTVB was 68.1 Gy (EQD2 71.8–72.7 Gy) for DL1,
71.5 Gy (EQD2 77.0–78.4 Gy) for DL2, and 74.8 Gy (EQD2 82.2–84.0 Gy) for DL3. A
simultaneous integrated boost technique was used to deliver the dose to the PTVs.
The planning objectives were to achieve:
1. Dose to 99% of volume (D99) of90% of the prescription dose to PTV1 and PTV2.
. Dose to 95% of volume (D95) of95% of the prescription dose to PTV1 and PTV2.
. Dose to 2% of volume (D2) of107% of the prescription dose to PTV1.
. For the boost study, dose to GTVB of 95% and 107% of the prescription dose to
GTVB
5. For spinal cord, maximum dose (Dmax)  46 Gy.
6. For brainstem, maximum dose (Dmax)  54 Gy.
7. For parotids, mean dose (Dmean) 20 Gy for unilateral sparing and 25 Gy for bilat-
eral sparing.
lanning techniques
All 20 patients had 2 plans generated (1 ﬁxed-ﬁeld IMRT and 1 double-arc
apidArc) for the standard dose study. The 10 patients in the boost study also had these
lans generated at each dose escalation level. All planswere generated using the Varian
clipse treatment planning system (Eclipse version 8.9.08, Varian Medical Systems,
alo Alto, CA) and designed to be delivered using 6-MV photons from a Varian Clinac iX
inear accelerator.
The ﬁxed-ﬁeld IMRT plans were optimized using 5–7 coplanar ﬁelds and delivered
sing the slidingwindow technique. RapidArc planswere optimized using 2 360 coplanar
rcs, with collimator angles of 20–45 to minimize the tongue-and-groove effect. Double
rcs have previously been shown to be superior to single arcs in improving target volume
overage and dose homogeneity.22 Both arcs were simultaneously optimized using the
Progressive Resolution Optimizer (PRO, version 8.9.08, Varian Medical Systems, Palo Alto,
CA,USA).13 Similar dose objectives and the “normal tissueobjective” functionwereused in
the optimization process for both ﬁxed-ﬁeld IMRT and RapidArc plans.
The ﬁnal dose calculation was performed using the Anisotropic Analytic Algorithm
(AAA, version 8.9.08) with a calculation grid of 2.5 mm.23 Couch attenuation using the
Exact image-guided radiation therapy couch top (thin) model in Eclipse was cor-
rected for 360 arc delivery in the RapidArc plans. All plans were performed by a
single planner.
Plan evaluation
Quantitative analysis of the plans was performed using dose-volume histo-
grams (DVHs). For the PTVs and GTVB, the values recorded were D99, D95, D50, D5,
and D2. Dose conformity was expressed as the Paddick Conformity Index (CIPaddick),
which is deﬁned as:
CIpaddick TV95TV XTV95V95 
where TV is the total target volume and TV95 is the target volume within the volume
eceiving at least 95% of the prescribed dose to the PTVs (V95). The CIPaddick scorewould
24e expected to decreasewith reduced plan conformity. For the spinal cord and brain-
stem, the DVH values recorded were Dmax, Dmean, D2, and volume receiving at least 35
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M. Teoh et al. / Medical Dosimetry 38 (2013) 18-2420Gy (V35Gy). For the parotid glands, Dmean andV35Gy, and for healthy tissue (body), Dmean,
5Gy, and V35Gy were recorded. MU for each plan were also recorded. The results of the
ﬁxed-ﬁeld IMRT and RapidArc plans were compared using the paired Student t-test.
Results
The patient, tumor, and target volume characteristics are sum-
marized in Table 1. The mean ( 1 SD) PTV1, PTV2, and GTVB vol-
mes were 456.8  133.9 cm3, 335.7  116.8 cm3, and 13.3  9.2
m3, respectively. An example of the dose distributions with ﬁxed-
eld IMRT and RapidArc for a patient in the boost study is shown in
ig. 1.
apidarc vs. IMRT (standard dose study)
Both techniques produced clinically acceptable plans and achieved
he planning objectives for PTVs. Target volume coverage was similar
etween RapidArc and IMRT plans. The mean values of the PTV dose
arameters for RapidArc and IMRT are summarized in Table 2. Small
ut statistically signiﬁcant differenceswere observed forD5 andD2 for
TV1, whichwere both 0.5% lower (on average) in the RapidArc plans.
or PTV2, D99 and D95 were lower (on average) by 0.6% and 0.4%,
respectively, in the RapidArc plans. Dose conformitywas signiﬁcantly
improved with RapidArc, with lower CIPaddick scores for both PTVs
summarized in Table 3).
The mean values of the OAR dose parameters for RapidArc and
MRT are summarized in Table 4. Neither technique exceeded Dmax
constraints for spinal cord and brainstem. We observed statistically
signiﬁcant differences in Dmean for both of these OARs, with higher
values in the RapidArc plans. No signiﬁcant difference was seen in con-
tralateral and ipsilateral parotid Dmean between the 2 techniques. V35Gy
for the contralateral parotid was signiﬁcantly lower with RapidArc, and
V5Gy for healthy tissue was signiﬁcantly higher in the RapidArc plans.
apidarc used fewerMU comparedwith IMRT (summarized in Table 5).
apidarc vs. IMRT (boost study)
Both techniques produced clinically acceptable plans at all 3 dose
scalation levels. Table 2 shows the mean values of the PTV dose pa-
ameters for RapidArc and IMRT. Planning objectives for target vol-
me coveragewere achieved,with no signiﬁcant differences for PTV1.
owever, D99 and D95 for PTV2 at all 3 dose levels were lower in the
apidArc plans. The largest differencewas seen at DL3, where D and
Table 1
Patient, tumor, and target volume characteristics
Patient no. Age Gender TNM stage
1 53 M T1N2b
2 45 F T4aN1
3 50 M T2N2a
4 47 F T4aN2b
5 55 M T2N2b
6 46 M T1N2b
7 69 M T3N2a
8 57 M T4 N2c
9 59 M T3N1
10 53 M T4aN2c
11 63 M T1N2b
12 60 M T2N2b
13 62 M T4bN1
14 66 M T3N0
15 59 M T2N2b
16 63 M T4 N1
17 71 M T4aN2b
18 44 M T1N2b
19 67 M T4aN2b
20 52 M T1N2b
ICC  Union of International Cancer Control.99
D95 were lower (on average) by 0.9% with RapidArc. For GTVB, small cbut statistically signiﬁcant differences were observed for D2 at DL2
and DL3 (0.4% and 0.5% higher with RapidArc, respectively), and D5 at
DL3 (0.5% higher with RapidArc).
Table 3 shows the CIPaddick scores of the PTVs calculated for each of
he dose levels. Dose conformity for both PTV1 and PTV2 was signiﬁ-
antly improved with RapidArc for all 3 dose escalation levels. The
argest difference in the CIPaddick score for PTV1 was at DL3, whereas
for PTV2, the largest difference was seen at DL1.
Table4 shows themeanvalues forOARdoseparameters forRapidArc
and IMRT. Neither technique exceeded Dmax constraints for spinal
cord and brainstem, as in the standard dose study. Higher spinal cord
DVH values were observed in the RapidArc plans for all 3 dose levels.
The largest difference in Dmax was seen at DL1, whichwas 2.5% higher
with RapidArc. For Dmean, the largest difference was seen at DL2,
whichwas 7.9% higherwith RapidArc. For the brainstem, therewas no
signiﬁcant difference in Dmax, but Dmean was higher in the RapidArc
lans by up to 15.4%.
Contralateral parotid Dmean was lower with RapidArc, with statis-
tically signiﬁcant differences seen in 2 of the 3 dose levels. The Dmean
was 0.9 and 1.0 Gy lowerwith RapidArc plans at DL1 and DL2, respec-
tively. V35Gy for the contralateral parotid was also signiﬁcantly lower
with RapidArc at all 3 dose levels, with the largest difference seen at
DL2 (26.3% lower with RapidArc). There were no signiﬁcant differ-
ences in ipsilateral parotid doses.
For healthy tissue, the most pronounced ﬁnding was for V5Gy,
which was higher in the RapidArc plans. The largest difference was
seen at DL1, which was 4.4% higher with RapidArc. RapidArc plans
used signiﬁcantly fewer MU compared with IMRT, with reductions of
up to 49.2% (summarized in Table 5).
Discussion
The concept of focal dose escalation to biologically radioresistant
regions in head and neck cancer has been of signiﬁcant interest in
recent years.7 To date, only one small planning study has reported on
the feasibility of focal dose escalation usingVMAT14 and to our knowl-
dge, there have been no published papers comparing VMAT with
onventional ﬁxed-ﬁeld IMRT in this context. First, our study has
emonstrated that for focal dose escalation to 18F-FDG–positive re-
ions in oropharyngeal cancer, RapidArc is able to achieve clinically
cceptable plans without exceeding dose constraints to critical OAR
e.g., spinal cord, brainstem). Second, our results show that RapidArc
C stage PTV1 (cm3) PTV2 (cm3) GTVB (cm
3)
337.7 397.8 11.8
225.5 225.6 2.7
392.7 602.1 14.1
331.8 292.7 28.4
475.5 375.5 1.4
380.3 434.8 3.9
382.9 376.7 26.3
779.9 200.1 16.1
392.4 257.9 12.6
666.5 114.4 15.6
368.7 325.6
573.5 440
424.4 382.9
432.9 457.2
409.8 242.4
658.3 156.4
435.1 392.8
402.3 430.3
597.5 283.1
469.1 335.7UIC
IVa
IVa
IVa
IVa
IVa
IVa
IVa
IV
III
IVa
IVa
IVa
IVb
III
IVa
IV
IVa
IVa
IVa
IVaan produce plans of comparable quality to conventional ﬁxed-ﬁeld
V2 (p
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M. Teoh et al. / Medical Dosimetry 38 (2013) 18-24 21IMRT. Target volume coverage was similar between RapidArc and
ﬁxed-ﬁeld IMRT plans at each dose escalation level. The absolute dif-
ference in statistically signiﬁcant PTV DVH parameters was small and
therefore unlikely to be clinically relevant. This is consistent with the
results of other studies, which have performed similar comparisons
Fig. 1. Example of dose distributions in IMRT and RapidArc plans for a patient in
escalation); and (E, F) plans at DL3 (15% dose escalation). PTV1 (red contour) and PT
4 Gy (dark blue line), respectively. GTVB (light green contour) is encompassed by thusing standard doses.22,25Several signiﬁcant ﬁndings were demonstrated in our study. First,
we observed signiﬁcantly improved dose conformity with RapidArc
compared with ﬁxed-ﬁeld IMRT. This is consistent with the prelimi-
nary results from the Ghent study,15 which reported improved bio-
logic conformality with VMAT. However, other studies have reported
ost study. (A, B) Plans at DL1 (5% dose escalation); (C, D) plans at DL2 (10% dose
ink contour) are encompassed by the 95% isodose curves of 65 Gy (orange line) and
% (A, B); 110% (C, D); and 115% (E, F) isodose curves (bright pink line).the boconﬂicting results, with inferior dose conformity seen with RapidArc
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M. Teoh et al. / Medical Dosimetry 38 (2013) 18-2422and VMAT.22 A possible reason for this discrepancy is that the ﬁxed
ﬁeld IMRT technique in these studies used a larger number of ﬁelds
(7–9) compared with our study, in which 5–7 ﬁelds were used, which
could have led to improved conformity and quality of the IMRT plans.
A 5- to 7-ﬁeld technique is the current IMRT solution at our institu-
tion, because our experience suggests that clinically acceptable plans,
which can be delivered in a shorter treatment time, are achievable
with this technique. Our ﬁndings are consistent with the results of
Bertelsen et al.’s study,25 which also used 5–7 ﬁelds in their IMRT
lans and demonstrated improved conformity with VMAT.
Another signiﬁcant ﬁnding in our study was the lower mean dose
eceived by the contralateral parotid gland with RapidArc compared
ith ﬁxed-ﬁeld IMRT. This is consistentwith the results of other stud-
es.22,25 The averagemean dose in the planswas higher than our plan-
ning objectives, which are based on recent QUANTEC guidelines.26
However, partial functional recovery can still occur with mean doses
of 25–35Gy, and therefore it is stillworth sparing asmuchof the gland
as possible even if planning objectives cannot be strictly met.26 Our
contralateral parotid mean doses were very similar to those found in
Vanetti et al.’s study22 but was higher than those in Bertelsen et al.’s
tudy.25 A possible explanation for this discrepancy is that in Bertel-
sen et al.’s study, the patient cohort included patients with primary
hypopharyngeal tumors that are likely to be situated further away
from the parotid glands, which are therefore potentially easier to
spare compared with the oropharyngeal cases in our study.
Neither RapidArc nor ﬁxed-ﬁeld IMRT exceeded the maximum
dose constraints for spinal cord and brainstem, with minimal differ-
ences in absolute Dmax. However we observed higher mean doses
ith RapidArc, whichweremore prominent in the boost study. These
esults conﬂict with published data that report signiﬁcantly lower
oses with VMAT.22 This could again be explained by differences in
planning and optimization techniques between studies. At our insti-
tution, the gantry angle positions for ﬁxed-ﬁeld IMRT are arranged to
maximize avoidance of the central OARs, which could explain the
Table 3
Mean values (1SD) of CIPaddick scores for PTVs*
PTV1 PTV2
IMRT RapidArc IMRT RapidArc
Standard dose
study
0.79 ( 0.04) 0.83 ( 0.03) 0.61 ( 0.03) 0.65 ( 0.03)
Dose escalation
study
DL1 0.79 ( 0.04) 0.82 ( 0.04) 0.60 ( 0.04) 0.65 ( 0.03)
DL2 0.79 ( 0.04) 0.82 ( 0.04) 0.61 ( 0.04) 0.65 ( 0.04)
DL3 0.77 ( 0.07) 0.81 ( 0.03) 0.60 ( 0.04) 0.64 ( 0.03)
Table 2
Mean values ( 1 SD) of PTV dose parameters between RapidArc and IMRT
Standard DL1
IMRT RapidArc IMRT Rap
PTV1
D95 (Gy) 62.7 ( 0.2) 62.8 ( 0.4) 62.8 ( 0.2) 62.8
D5 (Gy) 67.1 ( 0.3) 66.8 ( 0.3) 67.9 ( 0.8) 68.0
D2 (Gy) 67.6 ( 0.3) 67.3 ( 0.3) 68.8 ( 0.7) 68.9
PTV2
D99 (Gy) 51.4 ( 0.5) 51.1 ( 0.4) 51.4 ( 0.4) 51.0
D95 (Gy) 52.5 ( 0.4) 52.3 ( 0.3) 52.5 ( 0.3) 52.1
D5 (Gy) 59.1 ( 1.7) 59.0 ( 1.7) 59.5 ( 2.0) 59.7
GTVB
D95 (Gy) NA NA 68.2 ( 0.4) 68.3
D5 (Gy) NA NA 69.8 ( 0.4) 70.0
D2 (Gy) NA NA 69.9 ( 0.4) 70.2
tatistically signiﬁcant differences (p.05) shaded in gray.* All differences between IMRT and RapidArcwere statistically signiﬁcant (p 0.05).lower spinal cord and brainstem doses. Only the maximum dose was
set as a dose constraint in our study and it is possible that different
results would be obtained if additional constraints were used during
optimization. It may also be possible to obtain lower doses to these
OARs by application of avoidance sectors in the arcs and this will be
further assessed in future planning studies.
The major advantages with RapidArc/VMAT are a reduction in
treatment delivery time and MU,22 which could have a signiﬁcant
mpact on clinical service efﬁciency. Our study conﬁrmed a signiﬁcant
eduction inMUswith RapidArc, which was consistently seen at each
ose level in the boost study and the standard dose study. The main
eneﬁt using fewer MU is the reduction in scattered and leakage ra-
iation from the linear accelerator, and therefore a potential reduc-
ion in the risk of radiation-induced secondary malignancy. An inter-
sting observation in our study was the higher volumes of normal
issue receiving very-low-dose radiation (higher V5Gy) with RapidArc.
t is uncertain whether this phenomenon, which is also reported in
ther studies,27 will have a signiﬁcant impact on the risk of secondary
malignancy. Further investigation and longer follow-up of patients
treatedwith RapidArc/VMAT arewarranted tomore accurately quan-
tify this risk.
In our study, 18F-FDG-PET was used to deﬁne the regions for focal
dose escalation. 18F-FDG is the most widely available PET radiotracer
and is a potential surrogate marker of hypoxia, which is strongly as-
sociated with radioresistance.8 However, some studies have shown
that glucose metabolism and uptake do not always correlate to the
level of hypoxia in tumors.28 A further limitation of 18F-FDG is its
elatively low speciﬁcity (e.g., false positives in areas of inﬂamma-
ion).29 However, 18F-FDG uptake is also correlated with other fea-
ures associated with radioresistance, such as increased tumor cell
roliferation.30 Most local recurrences tend to occur within 18F-FDG–
positive regions and patients with 18F-FDG–positive disease have in-
ferior treatment outcomes.9 It would therefore be reasonable to use
18F-FDG-PET for the identiﬁcation of regions for dose escalation and
election of patients requiring intensiﬁcation of treatment.
The optimal schedule for PET-guided focal dose escalation is still
nknown. In our study, the escalated dose was planned to be deliv-
red in daily fractions throughout the 6-week treatment course. In the
hase I study by Madani et al.,11 the escalated dose was delivered in
he ﬁrst 2 weeks of treatment. The rationale for this is to allow the
oost to be delivered when there is the least anatomical and biologic
iscrepancy between the pretreatment PET and radiotherapy treat-
ent. It has been shown that temporal variations in PET signal can
ccur during the course of radiotherapy, which can lead to uncertain-
ies in deﬁning regions for dose escalation as treatment progresses.31
An argument against this up-front boost strategy is that for head-and-
DL2 DL3
IMRT RapidArc IMRT RapidArc
3) 62.8 ( 0.2) 62.7 ( 0.4) 62.7 ( 0.2) 62.7 ( 0.3)
8) 69.9 ( 1.8) 69.7 ( 1.8) 71.9 ( 2.8) 71.8 ( 3.0)
7) 71.5 ( 1.5) 71.6 ( 1.4) 74.3 ( 2.1) 74.4 ( 2.0)
5) 51.4 ( 0.5) 51.0 ( 0.4) 51.5 ( 0.5) 51.0 ( 0.4)
3) 52.5 ( 0.4) 52.1 ( 0.3) 52.5 ( 0.4) 52.0 ( 0.3)
0) 59.7 ( 1.8) 60.0 ( 1.7) 59.6 ( 1.9) 60.2 ( 1.8)
2) 71.3 ( 0.4) 71.3 ( 0.3) 74.3 ( 0.4) 74.4 ( 0.4)
3) 73.0 ( 0.3) 73.2 ( 0.2) 76.1 ( 0.2) 76.4 ( 0.2)
3) 73.1 ( 0.3) 73.4 ( 0.2) 76.3 ( 0.3) 76.6 ( 0.2)idArc
( 0.
( 0.
( 0.
( 0.
( 0.
( 2.
( 0.
( 0.
( 0.neck SCC, accelerated repopulation of tumor cells is expected to occur
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M. Teoh et al. / Medical Dosimetry 38 (2013) 18-24 23from around the third week of treatment, which may be a more ap-
propriate time for dose escalation.32 However, a delayed boost strat-
egy may not be feasible because dose escalation could be limited by
radiation-induced mucositis, which typically increases in severity
during the later stages of treatment.
In our study, a uniform dose escalation to the PET-positive regions
was applied (dose-painting by contours). Other studies have investi-
gated a dose-painting-by-numbers technique, in which the pre-
scribed boost dose varies according to the signal intensity of the indi-
vidual voxelswithin the target volume.10 Although this technique has
he potential beneﬁt of reducing the volume of tissues receiving very
igh radiation doses, it assumes that there is a linear relationship
etween radiotracer uptake and radiosensitivity, and could also be
nﬂuenced by spatial and temporal variations of radiotracer uptake
ffecting voxel intensity. Furthermore, precise setup limits to main-
ain the high level of dose modulation and highly sophisticated plan-
ing software, which is not currently widely available, would be
equired.
The limited accuracy of PET-based delineation of tumor boundar-
es remains a problematic issue. To date, there is no general consensus
n the best delineation method.33 In our study, we delineated the
oost volumes using a freehand method that is dependent on visual
nterpretation of the PET signal. This is the most commonly used
ethod but is prone to intra- and interobserver variability. Operator-
ndependent automatic segmentation tools may provide a more ob-
ective solution. Automatic segmentation requires a threshold of ra-
iotracer uptake to be deﬁned to identify the areas to be delineated.33
However, the optimal threshold level remains unclear and these
methods can also be affected by the partial volume effect, which can
underestimate the actual tumor size.34
One limitation to our studywas that coregistration of the 18F-FDG-
ET and radiotherapy planning CT images was not performed, be-
ause the immobilization shells could not be ﬁtted onto the existing
ET couch at our institution. Although this is an obvious problem for
able 4
ean values (1SD) of OAR dose parameters between RapidArc and IMRT
Standard Dose level 1
IMRT RapidArc IMRT
Spinal cord
Dmax. (Gy) 44.2 ( 0.8) 43.8 ( 1.1) 43.5 ( 0.7)
Dmean (Gy) 33.1 ( 2.3) 34.5 ( 1.7) 32.5 ( 2.5)
Brain stem
Dmax. (Gy) 45.1 ( 6.4) 44.8 ( 5.5) 42.6 ( 7.7)
Dmean (Gy) 12.8 ( 5.6) 14.2 ( 5.6) 11.0 ( 6.0)
Contra-lateral parotid
Dmean (Gy) 27.9 ( 6.6) 27.3 ( 6.3) 29.9 ( 5.4)
V35Gy (%) 34.1 ( 14.7) 26.6 ( 15.7) 40.1 ( 11.6)
Ipsilateral parotid
Dmean (Gy) 52.6 ( 11.9) 52.3 ( 12.4) 50.6 ( 12.7)
V35Gy (%) 81.9 ( 21.2) 79.5 ( 26.9) 78.2 ( 23.7)
Healthy tissue
Dmean (Gy) 14.0 ( 1.6) 14.2 ( 1.4) 14.0 ( 0.9)
V5Gy (%) 41.6 ( 5.7) 44.3 ( 5.2) 41.4 ( 3.2)
tatistically signiﬁcant differences (p .05) shaded in gray.
able 5
ean MU/fraction values ( 1 SD)
Study DL
Percentage escalation above
standard prescription dose
Standard dose study NA
Dose escalation study 1 5%
2 10%
3 15%ll differences between IMRT and RapidArc were statistically signiﬁcant (p  0.05).linical implementation, we were able to achieve the primary aims of
ur study, which were to evaluate the feasibility of focal dose escala-
ion with RapidArc and to compare these plans with ﬁxed-ﬁeld IMRT.
e have now developed an in-house PET headrest, which allows the
atient to be scanned in their immobilization shells, thereby permit-
ing rigid coregistration of PET and radiotherapy planning CT images.
omparative planning studies are prone to biases that have been dis-
ussed previously.22 We have attempted to reduce planner bias be-
ause all plans were generated by a single planner using the same
ptimization engine, dose objectives, and calculation algorithm. It
s worth noting that the plans were generated with planning ob-
ectives and techniques that are used clinically and were not de-
igned to push the optimizer to its maximum limit. It may be pos-
ible to achieve further improvements in dose distributions if more
ose-volume constraints were used in the optimization process.
inally, the increasing complexity of radiotherapy plans and dose
elivery would demand high levels of precision in geometrical ver-
ﬁcation procedures during treatment. Careful review of the cur-
ent standard protocol at our institution (planar kilovoltage and/or
one-beam CT imaging on days 1–3 and weekly cone-beam CT)
ould be required to ensure adequate levels of accuracy for future
ractical implementation of this strategy.
onclusions
Focal dose escalation to biologically radioresistant regions as de-
ned by 18F-FDG-PET is feasible with RapidArc. In this setting, Rapi-
dArc is able to achieve clinically acceptable plans with superior dose
conformity, improved sparing of parotid glands, and reduced MU
comparedwithﬁxed-ﬁeld IMRT. Larger clinical studies are required to
assess the impact of focal dose escalation on treatment outcome pa-
rameters, such as local control and toxicity.
Dose level 2 Dose level 3
rc IMRT RapidArc IMRT RapidArc
0.6) 43.7 ( 0.7) 44.4 ( 0.4) 43.5 ( 0.6) 44.5 ( 0.9)
2.3) 32.5 ( 2.6) 35.3 ( 1.8) 32.4 ( 2.6) 35.1 ( 1.7)
7.2) 42.7 ( 7.5) 42.7 ( 6.9) 42.3 ( 7.9) 43.7 ( 7.0)
6.3) 10.9 ( 5.9) 12.7 ( 6.1) 10.9 ( 5.9) 12.8 ( 6.1)
5.1) 30.3 ( 5.0) 29.3 ( 5.2) 30.3 ( 5.1) 29.7 ( 5.4)
12.0) 41.0 ( 11.1) 29.5 ( 12.4) 40.9 ( 10.6) 30.6 ( 12.5)
13.9) 50.4 ( 12.8) 50.5 ( 12.8) 50.4 ( 13.2) 50.1 ( 13.2)
31.5) 77.8 ( 24.1) 75.9 ( 30.9) 78.2 ( 25.4) 75.5 ( 31.7)
0.8) 14.0 ( 0.9) 14.2 ( 0.8) 14.0 ( 0.9) 14.3 ( 0.8)
3.3) 41.5 ( 3.1) 43.1 ( 3.5) 41.4 ( 3.1) 43.2 ( 3.4)
IMRT RapidArc Percentage reduction (%)
1109 ( 124) 667 ( 95) 39.9
1234 ( 111) 630 ( 108) 48.9
1220 ( 96) 632 ( 112) 48.2
1261 ( 118) 641 ( 94) 49.2T
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